science
Bipartisan Lawmakers Reintroduce Bill Ordering FTC and Treasury Review of Foreign Drug Manufacturing
Three lawmakers on July 15, 2026, reintroduced legislation directing the FTC and Treasury to examine foreign dependence in prescription drug manufacturing. The measure also targets risks from moving domestic facilities overseas.
Jul 15, 1:26 PM·1m read2 sources
americanbanker.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Three bipartisan lawmakers on July 15, 2026, reintroduced a bill that would require the Federal Trade Commission and the Department of the Treasury to investigate U.S. reliance on foreign countries for prescription drug production. The legislation directs scrutiny of whether relocating domestic manufacturing facilities overseas increases risks to the pharmaceutical supply chain.
The bill was introduced amid concern over the vulnerability of the U.S. pharmaceutical supply chain to disruption that could create national security issues. China holds a dominant role in producing many essential materials needed for medicines taken by Americans.
Five years earlier, a Department of Defense watchdog found that overreliance on foreign suppliers of medicines could harm national security. The same review determined that the Pentagon had failed to assess the risks of medicine shortages or develop strategies to mitigate disruptions in supply.
